Pipeline

In-house R&D projects open for out-licensing and/or co-development partnerships:

Pharmahungary Group runs in-house R&D projects for the development of therapies in cardiovascular and metabolic diseases up to phase II clinical stage. Investors and co-development partners are welcome:

The following in-house diagnostic R&D project of Pharmahungary Group is in the early clinical phase of development:

  • Infarnosys: (www.infarnosys.com): Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment
  • Vezics: (www.vezics.com): Modular and scalable chromatography platform for high-quality exosome isolation for biomarker and therapy.

Major funds from public R&D Grants:

Purchase and installation of a small-animal ultrasonic imaging system.      

Baross Gabor program, National Office for Research and Technology (INPHARMA project, awarded for 2010)

Development of Innovative technology platform for the preclinical screening of metabolic diseases.

Baross Gabor program, National Office for Research and Technology (METABBET project, awarded for the period of 2009-2011)

Technology transfer support of the cardiovascular R&D projects of Pharmahungary. Baross Gabor program, National Office for Research and Technology, awarded for 2009.

Development of “dietary foods for special medical purposes” for patients suffering from diabetes, atherosclerosis and coronary heart disease.

National Technology Platform (MED-FOOD project, awarded for the period of 2008-2012)

Platform of mouse and human embryonic stem cell-derived cardiomyocyte test systems for drug development.

Jedlik Anyos Grant (ES2HEART project, awarded for the period of 2008-2010)

Development of drug candidates based on genomics and chemoinformatics against myocardial infarction: inhibitors of matrix metalloproteinases.

Jedlik Anyos Grant (NKFP_06_A1_MMP_2006 project, awarded for the period of 2007-2010). For further information www.mmpharma.com.

Modulation of peroxynitrite-induced myocardial damage by pharmacological and gene therapies, and development of clinical  applications of peroxynitrite markers. 

GVOP Grant (GVOP-331-2004-04-0095_30, awarded for the period of 2005-2007)